List of Excipients in Branded Drug TAVALISSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rigel Pharmaceuticals Inc	TAVALISSE	fostamatinib	71332-001	FERRIC OXIDE RED
Rigel Pharmaceuticals Inc	TAVALISSE	fostamatinib	71332-001	FERRIC OXIDE YELLOW
Rigel Pharmaceuticals Inc	TAVALISSE	fostamatinib	71332-001	MAGNESIUM STEARATE
Rigel Pharmaceuticals Inc	TAVALISSE	fostamatinib	71332-001	MANNITOL
Rigel Pharmaceuticals Inc	TAVALISSE	fostamatinib	71332-001	POLYETHYLENE GLYCOL 3350
Rigel Pharmaceuticals Inc	TAVALISSE	fostamatinib	71332-001	POLYVINYL ALCOHOL

Tavalisse Excipient Strategy and Commercial Opportunities for Fostamatinib

Last updated: August 14, 2026

Tavalisse, the branded formulation of fostamatinib disodium hexahydrate, is an immediate-release oral tablet approved for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment. Its excipient system is conventional and comparatively accessible for generic development. The main commercial opportunities are generic tablets, alternate-strength products, dose-flexible packaging, global supply, and potentially differentiated oral formulations. The principal barriers are clinical substitution dynamics, limited market size, safety monitoring, and patent and regulatory review of any formulation or use claims.

What is Tavalisse and how is fostamatinib formulated?

Tavalisse contains fostamatinib disodium hexahydrate, a prodrug that is converted in vivo to R406, the active spleen tyrosine kinase inhibitor. The product is supplied as 100 mg and 150 mg immediate-release tablets. The approved indication is treatment of persistent or chronic immune thrombocytopenia in adults with an insufficient response to previous treatment [1].

Tavalisse composition and dosage forms

Attribute	Tavalisse product profile
Active ingredient	Fostamatinib disodium hexahydrate
Active metabolite	R406
Dosage form	Immediate-release film-coated tablet
Strengths	100 mg and 150 mg
Route	Oral
Initial adult dose	100 mg twice daily
Dose escalation	150 mg twice daily after four weeks if clinically appropriate
Key monitoring	Blood pressure, liver function, neutrophil count
Primary indication	Chronic immune thrombocytopenia
Developer and U.S. commercial holder	Rigel Pharmaceuticals
FDA approval	May 17, 2018

The U.S. prescribing information identifies conventional tablet excipients, including microcrystalline cellulose, croscarmellose sodium, povidone, sodium starch glycolate, magnesium stearate, and film-coating components such as polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. Colorants vary by strength and market presentation [1].

The formulation does not depend on a highly specialized delivery platform. It is therefore more exposed to conventional generic competition than products that require liposomes, depot technology, complex biologic excipients, or device integration.

What excipients are used in Tavalisse tablets?

The core excipient strategy is based on direct-compression or conventional wet-granulation functionality: a diluent, disintegrants, a binder, a lubricant, and a film coat.

Excipient class	Likely function in Tavalisse	Commercial relevance
Microcrystalline cellulose	Filler, compressibility aid	Broad supplier base and low substitution risk
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup
Sodium starch glycolate	Superdisintegrant	Provides additional disintegration capacity
Povidone	Binder and granulation aid	Available in multiple molecular-weight grades
Magnesium stearate	Lubricant	Requires control of concentration and blending time
Polyvinyl alcohol	Film former	Standard aqueous coating component
Polyethylene glycol	Plasticizer	Supports coating flexibility
Titanium dioxide and talc	Opacity, appearance, processing	Subject to jurisdiction-specific regulatory scrutiny
Colorants	Strength identification	Supports dose differentiation and adherence

The dual-disintegrant architecture is commercially relevant. A generic developer would need to demonstrate that tablet disintegration, dissolution, hardness, friability, and stability remain comparable while controlling lubricant sensitivity and coating performance.

The most important formulation variables are likely:

1. Fostamatinib loading and dose uniformity.
2. Dissolution across the applicable pH range.
3. Moisture protection and chemical stability.
4. Tablet robustness during packaging and distribution.
5. Color and visual differentiation between 100 mg and 150 mg tablets.
6. Compatibility between the phosphate-containing prodrug and excipients.
7. Reproducibility of conversion to active metabolite after oral administration.

What excipient strategy is best for a generic Tavalisse product?

A conventional immediate-release tablet is the lowest-risk development route. The reference product’s excipient system gives developers several options without requiring an exact qualitative and quantitative copy, subject to FDA bioequivalence and product-quality requirements.

Option 1: Reference-like tablet

A reference-like formulation would use the same major functional classes:

• Microcrystalline cellulose as the principal filler.
• Povidone as binder.
• Croscarmellose sodium and sodium starch glycolate as disintegrants.
• Magnesium stearate as lubricant.
• A standard aqueous film coat.

This approach can reduce formulation risk and simplify dissolution matching. Its disadvantages are limited differentiation and potential dependence on the same commodity supply chain.

Option 2: Simplified excipient system

A developer could use a single superdisintegrant, a different filler, or a direct-compression platform. Possible alternatives include lactose monohydrate, mannitol, dibasic calcium phosphate, crospovidone, or low-substituted hydroxypropyl cellulose.

The commercial benefit is procurement flexibility. The regulatory risk is that changes in tablet density, wettability, compression force, or excipient interaction may shift dissolution or exposure.

Option 3: Modified-release or liquid formulation

A liquid, orally disintegrating tablet, or modified-release product could create a differentiated product, but each route requires a stronger commercial rationale. The approved product is already an oral tablet with dose escalation from 100 mg to 150 mg twice daily. A novel product would need to solve a clear problem, such as swallowing difficulty, pediatric administration, dose flexibility, or adherence.

The clinical and regulatory burden would be higher than for a standard ANDA tablet. A liquid formulation would also create preservative, microbial-control, taste-masking, packaging, and in-use stability requirements.

What formulation patents protect Tavalisse?

Publicly available product information establishes that Tavalisse uses a conventional immediate-release tablet. The commercial assessment should distinguish three potential layers of intellectual property:

1. Compound and salt patents covering fostamatinib or its disodium salt.
2. Manufacturing patents covering synthesis, intermediates, purification, or crystalline forms.
3. Formulation or method-of-use patents covering tablet composition, dosing, or treatment of thrombocytopenia.

The existence of a conventional excipient system does not eliminate patent risk. A generic developer must review the FDA Orange Book, published patent families, terminal disclaimers, patent-term adjustment, and any relevant Paragraph IV certifications before relying on an excipient substitution strategy.

Orange Book and Paragraph IV status

Tavalisse is a small-molecule product, so generic applicants would normally use the ANDA pathway rather than a biosimilar pathway. An ANDA applicant must address listed patents through certification under Paragraph I, II, III, or IV, or a section viii statement for a method-of-use patent.

A Paragraph IV certification could trigger patent litigation within 45 days of notice. The commercial impact depends on:

• Whether the listed patent covers the active ingredient, formulation, or method of use.
• Whether the patent is the only barrier to approval.
• Whether a 30-month stay is triggered.
• Whether the applicant has a first-filer position.
• Whether the patent holder settles, obtains a preliminary injunction, or loses at trial.
• Whether the generic label can omit protected indications through a section viii carve-out.

Patent expiration should be evaluated patent by patent. The relevant date is not necessarily the earliest composition-of-matter expiration because listed formulation or method-of-use patents may extend the practical launch barrier.

When does Tavalisse lose exclusivity?

Tavalisse received FDA approval in 2018 for an orphan indication. Orphan-drug exclusivity generally lasts seven years from approval, subject to statutory exceptions. For the original U.S. approval, the seven-year period would ordinarily run into 2025 [2].

The exclusivity timeline is separate from patent expiration and from FDA approval exclusivity.

Exclusivity category	Tavalisse relevance
Orphan-drug exclusivity	Seven years from approval for the approved orphan indication, subject to statutory exceptions
NCE exclusivity	Must be confirmed from the FDA Orange Book and regulatory records
Three-year exclusivity	Could apply to certain supplemental approvals involving new clinical investigations
Patent protection	Depends on issued claims, patent-term adjustment, terminal disclaimers, and listed patents
Pediatric exclusivity	Applies only if FDA grants the additional six-month extension
Biosimilar exclusivity	Not applicable because fostamatinib is a small molecule

Loss of orphan exclusivity does not automatically result in immediate generic entry. ANDA approval still depends on patent certifications, litigation outcomes, regulatory review, and commercial launch decisions.

What generic entry risks exist for Tavalisse?

The generic entry risk is structurally meaningful because the product is a tablet with standard excipients and no delivery device. The market is not necessarily easy to penetrate because the drug is used in a specialist hematology setting and has safety-monitoring requirements.

Technical barriers

A generic applicant would need to establish:

• Pharmaceutical equivalence.
• Bioequivalence.
• Comparable dissolution.
• Adequate stability.
• Acceptable impurity control.
• Consistent dose uniformity.
• Commercial-scale tablet manufacturability.

Fostamatinib’s conversion to R406 makes metabolite exposure important. A formulation that changes absorption rate or extent could affect the active metabolite profile, even if the prodrug assay appears acceptable. This makes comparative pharmacokinetic design and analytical method validation important.

Clinical and commercial barriers

Tavalisse has a narrower market than broad hematology products. Treatment is generally reserved for adults with chronic immune thrombocytopenia after prior therapies. Physicians may continue branded treatment when platelet response, tolerability, and monitoring routines are established.

The principal commercial risks for a generic entrant are:

• Limited total patient volume.
• Payer restrictions and specialty-pharmacy distribution.
• Need for blood-pressure and liver-function monitoring.
• Variable duration of treatment.
• Competition from thrombopoietin receptor agonists, rituximab, splenectomy, and other ITP therapies.
• Potential reluctance to switch patients who are responding to treatment.
• Lower price realization in a specialty product with a small prescriber base.

What commercial opportunities exist for Tavalisse excipients?

The most attractive opportunities are supply-chain and lifecycle opportunities rather than highly novel excipient technologies.

Excipient supply opportunities

A supplier can target:

• Direct-compression microcrystalline cellulose grades.
• Low-moisture disintegrants.
• Co-processed filler-disintegrant systems.
• Low-peroxide povidone.
• Magnesium stearate grades optimized for lubrication without dissolution slowdown.
• Ready-to-use film-coating systems.
• Titanium-dioxide-free coating systems for markets with tighter restrictions.
• Color systems that preserve strength differentiation across jurisdictions.

The value proposition is manufacturing consistency, reduced batch failure, and supply continuity rather than a new therapeutic effect.

Reformulation opportunities

Potential differentiated products include:

• A lower-swallowing-burden tablet.
• An orally disintegrating tablet for patients with dysphagia.
• A sprinkle formulation for controlled administration.
• A pediatric or geriatric liquid formulation.
• A blister-pack presentation aligned with twice-daily dosing.
• A lower-cost tablet using a simplified excipient system.
• A formulation with improved moisture protection for tropical markets.

Each product would need a defined clinical or commercial purpose. A formulation change alone is unlikely to command a premium unless it improves adherence, administration, tolerability, or distribution economics.

Geographic opportunities

Fostamatinib’s commercial opportunity varies by market. The United States is the primary reference market for Tavalisse. Expansion into Europe, Japan, and other regions depends on local approval, reimbursement, orphan designation, and the strength of competing ITP therapies.

For excipient suppliers, geographic opportunity is broader than branded-drug opportunity because generic and regional manufacturers may seek local sourcing, dual sourcing, or compliance with local restrictions on colorants and titanium dioxide.

How does Tavalisse compare with competing ITP drugs?

Product or class	Dosage form	Main commercial distinction	Excipient opportunity
Tavalisse, fostamatinib	Immediate-release tablet	Oral SYK inhibition for chronic ITP	Conventional generic and differentiated oral solid dosage
Promacta, eltrombopag	Tablet and oral suspension	Thrombopoietin receptor agonist; food and polyvalent-cation restrictions	Suspension, taste masking, and pediatric formulation
Doptelet, avatrombopag	Tablet	Thrombopoietin receptor agonist	Conventional solid-dose competition
Nplate, romiplostim	Injectable biologic	Weekly injectable administration	Biologic formulation and cold-chain supply
Rituxan and biosimilars	Intravenous biologic	Anti-CD20 therapy	Biosimilar manufacturing, formulation, and infusion supply

Tavalisse has no biosimilar risk because fostamatinib is a chemically synthesized small molecule. Its direct generic risk is more relevant than biologic competition, while therapeutic substitution risk comes from other ITP products.

What is the revenue exposure and market outlook for Tavalisse?

Tavalisse revenue depends on patient persistence, payer coverage, treatment sequencing, and the ability to maintain platelet response. The product’s commercial value is concentrated in a chronic, treatment-experienced ITP population rather than a high-volume primary-care market.

Rigel has reported Tavalisse as a core commercial product and has pursued international commercialization and collaboration arrangements. Revenue exposure is therefore concentrated in:

• U.S. net product sales.
• Partner or license income outside the United States.
• Label expansion or additional hematology uses.
• Price erosion after generic entry.
• Patient retention in a specialty market.

A generic entrant could capture share without replacing the entire branded market. Physicians may reserve the generic for new starts or price-sensitive plans while maintaining the branded product for established responders.

What licensing deals and partnerships affect Tavalisse?

Rigel has used regional and commercial partnerships to expand fostamatinib access. Kissei Pharmaceutical has been associated with development and commercialization rights in Japan, while other territory-specific arrangements have supported international distribution [3].

Licensing arrangements can affect excipient opportunities because the same active ingredient may be manufactured under different regional specifications. Differences may arise in:

• Approved colorants.
• Film-coat composition.
• Tablet imprinting.
• Packaging moisture barrier.
• Local excipient restrictions.
• Pharmacopoeial standards.
• Manufacturing-site qualification.

A supplier that can provide harmonized excipient systems across U.S., European, and Asian manufacturing sites may have an advantage over a supplier offering only a single-market grade.

How strong is the Tavalisse patent estate?

The patent estate should be treated as potentially meaningful but not necessarily impenetrable. The conventional tablet formulation limits the ability to create broad, defensible formulation claims unless the patent family includes specific composition, dissolution, stability, salt, polymorph, or manufacturing limitations.

Patent strength is highest where claims cover:

• The active compound or a necessary salt.
• A defined crystalline form.
• A synthesis step that is difficult to design around.
• A clinically necessary dosing regimen.
• A formulation with demonstrated pharmacokinetic or stability advantages.

Patent strength is weaker where claims depend on routine excipient selection, broad functional language, or tablet parameters that a generic manufacturer can avoid through a conventional alternative.

Key Takeaways

• Tavalisse is an immediate-release fostamatinib tablet available in 100 mg and 150 mg strengths.
• Its excipient system is conventional and supports multiple generic development routes.
• The best near-term excipient opportunities are supply reliability, co-processed excipients, film-coating systems, and differentiated oral solid dosage forms.
• A liquid, orally disintegrating, or pediatric formulation could create lifecycle value but would require a clear clinical benefit.
• Tavalisse has small-molecule generic risk, not biosimilar risk.
• Orphan exclusivity from the 2018 approval generally extended into 2025, but patent and regulatory barriers must be assessed separately.
• The main commercial barriers are specialty-market size, safety monitoring, reimbursement, and competition from thrombopoietin receptor agonists.
• Patent risk depends on the specific Orange Book listings and issued claims, not on the use of conventional excipients alone.

FAQs

Can a generic Tavalisse use different excipients?

Yes. An ANDA applicant generally does not need to duplicate every inactive ingredient, but the product must meet pharmaceutical-equivalence, bioequivalence, quality, stability, and labeling requirements.

Is fostamatinib suitable for an orally disintegrating tablet?

Potentially, but development would need to address taste, dose loading, tablet strength, moisture sensitivity, disintegration, and bioequivalence. The commercial case is strongest for patients with swallowing difficulty or adherence problems.

Does Tavalisse have biosimilar competition?

No. Fostamatinib is a small-molecule drug. Competition would arise through ANDA-based generic products or therapeutic alternatives, not biosimilars.

Which excipient issue is most likely to affect generic Tavalisse dissolution?

Magnesium stearate concentration and blending time can affect wetting and dissolution. Disintegrant grade, binder level, compression force, and tablet porosity are also important variables.

Could a generic company launch before every Tavalisse patent expires?

Possibly, if it obtains a favorable Paragraph IV outcome, reaches a settlement permitting an earlier launch, uses a section viii carve-out for protected methods of use, or determines that relevant patents are invalid, unenforceable, or not infringed. FDA approval and commercial launch timing would remain separate questions.

References

1. U.S. Food and Drug Administration. (2023). Tavalisse (fostamatinib disodium) prescribing information. Rigel Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. Rigel Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.